Development of potential orphan drug therapy of intravesical liposomal tacrolimus for hemorrhagic cystitis due to increased local drug exposure

Journal of Urology

Volumn 189, Issue 4, 2013, Pages 1553-1558

  Nirmal, Jayabalan ^a   Tyagi, Pradeep ^b   Chancellor, Michael B ^a   Kaufman, Jonathan ^c   Anthony, Michele ^c   Chancellor, David D ^c   Chen, Yen Ta ^d   Chuang, Yao Chi ^d  

^a OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Lipella Pharmaceuticals Inc   (United States)

^d CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

cystitis; liposomes; pharmacokinetics; tacrolimus; urinary bladder

Indexed keywords

LIPOSOMAL TACROLIMUS; LIPOSOME; ORPHAN DRUG; TACROLIMUS; UNCLASSIFIED DRUG;

ANESTHESIA; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG URINE LEVEL; HEMORRHAGIC CYSTITIS; LIPOSOMAL DELIVERY; MICROPARTICLE ENZYME IMMUNOASSAY; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; URINALYSIS;

ADMINISTRATION, INTRAVESICAL; ANIMALS; CYSTITIS; HEMORRHAGE; IMMUNOSUPPRESSIVE AGENTS; LIPOSOMES; ORPHAN DRUG PRODUCTION; RATS; TACROLIMUS;

EID: 84875954977     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.10.123     Document Type: Article

References (17)

1. K. Migita, K. Eguchi FK 506-mediated T-cell apoptosis induction Transplant Proc 33 2001 2292
2. M. Naesens, D.R. Kuypers, M. Sarwal Calcineurin inhibitor nephrotoxicity Clin J Am Soc Nephrol 4 2009 481
3. Y. Akar, G. Yucel, A. Durukan Systemic toxicity of tacrolimus given by various routes and the response to dose reduction Clin Experiment Ophthalmol 33 2005 53
4. A.K. Ebert, W.H. Rosch, T. Vogt Safety and tolerability of adjuvant topical tacrolimus treatment in boys with lichen sclerosus: a prospective phase 2 study Eur Urol 54 2008 932
5. Y.C. Chuang, P. Tyagi, H.Y. Huang Intravesical immune suppression by liposomal tacrolimus in cyclophosphamide-induced inflammatory cystitis Neurourol Urodyn 30 2011 421
6. M.P. Perez-Brayfield, A.J. Kirsch Hemorrhagic Cystitis Emedicine 2009 http://emedicine.medscape.com Updated September 18, 2009
7. A. Fahr, P. Van-Hoogevest, J. Kuntsche Lipophilic drug transfer between liposomal and biological membranes: what does it mean for parenteral and oral drug delivery? J Liposome Res 16 2006 281
8. A. Fahr, X. Liu Drug delivery strategies for poorly water-soluble drugs Expert Opin Drug Deliv 4 2007 403
9. K. Reimer, W. Fleischer, B. Brogmann Povidone-iodine liposomes - -an overview Dermatology 195 1997 93
10. A. Giannantoni, S.M. Di Stasi, M.B. Chancellor New frontiers in intravesical therapies and drug delivery Eur Urol 50 2006 1183
11. P. Tyagi, P.C. Wu, M. Chancellor Recent advances in intravesical drug/gene delivery Mol Pharm 3 2006 369
12. M.O. Fraser, Y.C. Chuang, P. Tyagi Intravesical liposome administration - a novel treatment for hyperactive bladder in the rat Urology 61 2003 656
13. Y.C. Chuang, W.C. Lee, P.H. Chiang Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome J Urol 182 2009 1393
14. M. Erdogan, J.R. Wright, V.C. McAlister Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model Br J Dermatol 146 2002 964
15. M. Foldvari, C. Oguejiofor, S. Afridi Liposome encapsulated prostaglandin E1 in erectile dysfunction: correlation between in vitro delivery through foreskin and efficacy in patients Urology 52 1998 838
16. A.C. Hoffmann, P. Wild, C. Leicht MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy Neoplasia 12 2010 628
17. M. Trevisani, D. Gazzieri, F. Benvenuti Ethanol causes inflammation in the airways by a neurogenic and TRPV1-dependent mechanism J Pharmacol Exp Ther 309 2004 1167